Windtree Therapeutics Inc (WINT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Windtree Therapeutics Inc (WINT) has a cash flow conversion efficiency ratio of 0.549x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.37 Million) by net assets ($-11.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Windtree Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Windtree Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Windtree Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check WINT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Windtree Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Windtree Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MEDICOX Co. Ltd
KQ:054180
|
-0.040x |
|
Oxbridge Re Holdings Equity Warrant
NASDAQ:OXBRW
|
0.067x |
|
Town Centre Securities PLC
LSE:TOWN
|
0.032x |
|
Faron Pharmaceuticals Oy
LSE:FARN
|
0.000x |
|
Ireka Corporation Bhd
KLSE:8834
|
0.003x |
|
R.E.A. Holdings plc
LSE:RE
|
0.120x |
|
Naked Wines plc
LSE:WINE
|
0.096x |
|
Ecoclime Group AB Series B
ST:ECC-B
|
0.000x |
Annual Cash Flow Conversion Efficiency for Windtree Therapeutics Inc (1995–2024)
The table below shows the annual cash flow conversion efficiency of Windtree Therapeutics Inc from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see Windtree Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $10.00 Million | $-15.40 Million | -1.541x | +61.12% |
| 2023-12-31 | $3.39 Million | $-13.44 Million | -3.963x | -103.95% |
| 2022-12-31 | $10.01 Million | $-19.45 Million | -1.943x | -243.85% |
| 2021-12-31 | $41.88 Million | $-23.66 Million | -0.565x | -55.24% |
| 2020-12-31 | $69.55 Million | $-25.32 Million | -0.364x | -10.59% |
| 2019-12-31 | $74.94 Million | $-24.66 Million | -0.329x | -42.06% |
| 2018-12-31 | $68.11 Million | $-15.78 Million | -0.232x | -126.33% |
| 2017-12-31 | $-23.92 Million | $-21.05 Million | 0.880x | -24.48% |
| 2016-12-31 | $-28.83 Million | $-33.59 Million | 1.165x | +128.74% |
| 2015-12-31 | $8.27 Million | $-33.50 Million | -4.053x | -89.02% |
| 2014-12-31 | $19.20 Million | $-41.17 Million | -2.144x | -210.09% |
| 2013-12-31 | $58.50 Million | $-40.45 Million | -0.692x | +62.88% |
| 2012-12-31 | $17.65 Million | $-32.88 Million | -1.863x | +89.63% |
| 2011-12-31 | $1.26 Million | $-22.70 Million | -17.957x | -345.86% |
| 2010-12-31 | $6.03 Million | $-24.27 Million | -4.028x | +34.08% |
| 2009-12-31 | $4.49 Million | $-27.41 Million | -6.110x | -110.38% |
| 2008-12-31 | $10.93 Million | $-31.75 Million | -2.904x | -283.16% |
| 2007-12-31 | $38.78 Million | $-29.39 Million | -0.758x | +72.74% |
| 2006-12-31 | $14.32 Million | $-39.83 Million | -2.781x | -67.99% |
| 2005-12-31 | $34.84 Million | $-57.67 Million | -1.655x | -4.74% |
| 2004-12-31 | $21.10 Million | $-33.34 Million | -1.580x | -63.71% |
| 2003-12-31 | $24.30 Million | $-23.46 Million | -0.965x | -6.06% |
| 2002-12-31 | $14.76 Million | $-13.44 Million | -0.910x | -26.31% |
| 2001-12-31 | $17.62 Million | $-12.70 Million | -0.721x | -102.25% |
| 2000-12-31 | $16.44 Million | $-5.86 Million | -0.356x | +73.23% |
| 1999-12-31 | $3.11 Million | $-4.14 Million | -1.331x | +31.49% |
| 1998-12-31 | $3.50 Million | $-6.80 Million | -1.943x | -319.66% |
| 1997-12-31 | $10.80 Million | $-5.00 Million | -0.463x | +64.73% |
| 1996-12-31 | $1.60 Million | $-2.10 Million | -1.313x | -89.00% |
| 1995-12-31 | $3.60 Million | $-2.50 Million | -0.694x | -- |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more